IL-17A produced by invariant natural killer T cells and CD3+CD56+αGalcer-CD1d tetramer– T cells promote liver fibrosis in patients with primary biliary cholangitis

Hongyu Jia,Jianing Chen,Xujun Zhang,Kefan Bi,Hetong Zhou,Tianxing Liu,Jia Xu,Hongyan Diao
DOI: https://doi.org/10.1002/jlb.2a0622-586rrrr
2022-01-01
Journal of Leukocyte Biology
Abstract:Abstract Primary biliary cholangitis (PBC) is characterized as interlobular bile duct injury and fibrosis, which results from the loss of tolerance to self-antigens. However, the exact pathologic mechanism leading to injury and fibrosis in PBC patients is not fully understood. Therefore, in this study, we examined the role of the T cell subsets in PBC patients and healthy controls (HCs). A higher number of invariant Natual killer T (iNKT) cells as well as CD3+CD56+ αGalcer-CD1d tetramer– T cells were found in patients with PBC compared with HCs. Moreover, these 2 T subpopulations produced significantly higher levels of Interleukin (IL)-17A in PBC patients than those in in HCs, which has also been positively correlated with the disease severity. Furthermore, the level of IL-17A produced by these 2 subpopulations was increased after stimulation of the autoantibodies in patients with PBC. Also, the elevated IL-17A levels promoted the PBC-related fibrosis, thus presenting a change in frequencies and functions of these cell phenotypes in the deterioration of the duct damage-related fibrosis. This study clarified PBC patients’ distinct T subpopulations characteristics, providing evidence-based diagnostic and therapies for these patients. The correlation between unclassical T subsets and IL-17A may provide a novel target for the immunotherapy of PBC.
What problem does this paper attempt to address?